U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)
YONGIN, South Korea, July 31, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of the Biologics License App...
GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent
* Striving to further expand its territory to Africa and the Middle East from Southeast Asia and Latin America * "Will create synergy between international procurement market and private markets of individual countries so as to boost sales and profitability" YONGIN, South Korea, July 21, 2023...
GC Biopharma receives a business license for the construction of a plasma fractionation plant and technology transfer in Indonesia
* In recognition of securing high-caliber technology in manufacturing plasma derivatives and a track record of overseas plasma fractionation plant construction and technology transfer YONGIN, South Korea, June 1, 2023 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, anno...
GC Biopharma celebrates 'World Hemophilia Day'
* To display a large media façade on its Yong-in R&D Center YONGIN, South Korea, April 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, takes part in a campaign to celebrate World Hemophilia Day. The company announced that a l...
GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology
* Entered into an acquisition deal of 3 programs YONGIN, South Korea, Feb. 27, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : ...
GC Biopharma Receives WHO Pre-Qualification for BARYCELA
YONGIN, South Korea, Feb. 19, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has granted prequalification for BARYCELA, GC Biopharma's varicella vaccine. WHO prequalificatio...
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea
YONGIN, South Korea, Feb. 8, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has awarded prequalification to filling and finish plant onFebruary 3 2023, located in Ochang, South...
GC Biopharma and Speragen Sponsored an Externally Led - Patient Focused Drug Development with FDA Attendance
YONGIN, South Korea and AUSTIN, Texas, Aug. 30 2022 /PRNewswire/ -- GC Biopharma (006280.KS) and Speragen today announced that a joint Externally Led - Patient-Focused Drug Development (EL-PFDD) meeting hosted by SSADH Association and attended by the U.S. FDA and other stakeholders was held to a...
GC Pharma lights up to celebrate 'World Hemophilia Day'
YONGIN, South Korea, April 17, 2020 /PRNewswire/ -- GC Pharma (formerly known
as Green Cross Corporation), a South Korean biopharmaceutical company,
participate in campaign to celebrate World Hemophilia Day.
GC Pharma Reports Full Year 2019 Results
All consolidated entities revenues grew plus compared to prior year YONGIN, South Korea, Feb. 12, 2020 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended31 December 201...
GC Pharma Reports Q3 2019 Results
YONGIN, South Korea, Oct. 30, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedSeptember 30, 2019. Key Figures Q3 2019(1) Growth(1) Total revenues K...
GC Pharma Reports Q2 2019 Results
YONGIN, South Korea, July 30, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedJune 30, 2019. Key Figures Q2 2019(1) Growth(1) Total revenues KRW 35...
GC Pharma Reports Q1 2019 Results
YONGIN, South Korea, April 30, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedMarch 31, 2019. Key Figures Q1 2018(1) Growth(1) Total revenues KRW 2...
Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug
YONGIN, South Korea, April 4, 2019 /PRNewswire/ -- Clinigen K.K. and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280) today announced an exclusive licensing agreement inJapan to commercialize Hunterase (Idursulfase-beta) ICV, a human recombinant iduronate-2-sulfatase (IDS) used...
GC Pharma Reports Full Year 2018 Results
Delivers Continued Momentum in 2018 Through Broadly-based Sales Growth YONGIN, South Korea, Feb. 12, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended31 December ...
GC Pharma Reports Q3 2018 Results
YONGIN, South Korea, Oct. 30, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedSeptember 30, 2018. Key Figures Q3 2018(1) Growth(1) Total revenues K...
GC Pharma Reports Q2 2018 Results
YONGIN, South Korea, July 31, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedJune 30, 2018. Key Figures Q2 2018(1) Growth(1) Total revenues KRW 34...
GC Pharma to Establish Curevo - a Seattle-based New Company Dedicated to Development of New Vaccines
YONGIN, South Korea, May 20, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced the establishment of Curevo Inc. ("Curevo"). The newly establishedSeattle-based company's goal is to support GC Pharma's...
GC Pharma Reports Q1 2018 Results
YONGIN, South Korea, April 27, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedMarch 31, 2018. Key Figures Q1 2018(1) Growth(1) Total revenues K...
GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant
YONGIN, South Korea, Feb. 14, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm") (SEHK: 0950) ...
